Kyungdong Pharmaceutical and Asimov Complete AI-Driven Cell Line Development for Next-Generation Biosimilar Antibody
核心洞察
Kyungdong Pharmaceutical (搜索) and Asimov (搜索) successfully completed a cell line development campaign for a biosimilar antibody candidate using Asimov's AI-native synthetic biology platform.
The collaboration utilized the CHO Edge System, integrating a GS knock-out CHO host, hyperactive transposase, and AI-driven genetic design software to achieve high titer and product quality.
The high-performing production cell line lays the foundation for downstream process development, large-scale manufacturing, and eventual commercialization of the biosimilar.
Kyungdong Pharmaceutical (搜索), in collaboration with Asimov (搜索), has successfully completed a cell line development campaign for a next-generation biosimilar antibody candidate, the companies announced on August 9, 2026. The milestone marks a significant step in Kyungdong's strategic expansion from its established prescription medicine portfolio into the biologics market, securing a high-performing production cell line that underpins future process development, large-scale manufacturing, and eventual commercialization.
The collaboration leveraged Asimov (搜索)'s proprietary CHO Edge System, an integrated platform that combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library, and Kernel — Asimov's AI-driven genetic design software. According to the announcement, the resulting cell line achieved a high titer while maintaining product quality, providing a robust foundation for subsequent development stages.
"We are excited to be partnering with Kyungdong Pharmaceutical (搜索), one of the leading pharmaceutical companies in Korea, and to contribute to the development of its next-generation biosimilar," said Alec Nielsen, co-founder and CEO of Asimov (搜索). "This collaboration demonstrated the high productivity and development efficiency of our CHO Edge System while maintaining product quality, and we look forward to continuing our collaboration with Kyungdong Pharmaceutical."
Ryu Gi-sung, CEO of Kyungdong Pharmaceutical (搜索), expressed similar enthusiasm: "We are highly satisfied with the achievements of our collaboration with Asimov (搜索). As we embark on significantly expanding our biopharmaceutical business, we will strive to work with world-class partners such as Asimov to help bring the treatment options patients need to patients around the globe."
AI-Driven Synthetic Biology Platform
Asimov (搜索), founded by bioengineers from MIT and Boston University and headquartered in Boston, has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. The company's mission centers on advancing the ability to design living systems, enabling biotechnologies with outsized societal benefit through a synthetic biology platform spanning from cells to software.
The CHO Edge System represents a convergence of advanced host engineering and computational design. By employing a GS knock-out CHO host paired with a hyperactive transposase, the system facilitates stable and efficient integration of transgenes. Kernel, the AI-driven genetic design software, optimizes genetic constructs to balance productivity and product quality — critical parameters for biosimilar development where demonstrating similarity to the reference product is paramount.
Kyungdong's Biologics Expansion
Kyungdong Pharmaceutical (搜索) has built its reputation through sustained investment in research and development and formulation technologies across cardiovascular, gastrointestinal, and respiratory diseases. The successful completion of this cell line development campaign signals the company's commitment to diversifying into next-generation biopharmaceutical R&D while accelerating its expansion into global markets.
The program was specifically undertaken with the goal of developing a production cell line capable of delivering both high productivity and product quality — twin imperatives for biosimilar manufacturers seeking to compete on cost while meeting stringent regulatory requirements for comparability.
Foundation for Commercialization
With the cell line development phase now complete, Kyungdong is positioned to advance into downstream process development. The high-titer cell line provides a critical starting point for process characterization, scale-up, and eventual technology transfer to good manufacturing practice (GMP) facilities. While the specific reference product and therapeutic area for the biosimilar candidate were not disclosed, the achievement underscores the growing role of AI-enabled platforms in accelerating biologic drug development timelines.